AZNH - ETF AI Analysis

Top Page

AstraZeneca PLC ADRhedged (AZNH)

Rating:79Outperform

Price Target:―

AZNH’s rating suggests it is a solid-quality ETF, largely driven by its dominant holding in AstraZeneca (AZN), which makes up almost the entire fund and benefits from strong financial performance, positive earnings commentary, and supportive technical trends. However, investors should be aware that this heavy concentration in a single company and the risks tied to AstraZeneca’s high valuation and potential policy or regional challenges are the main factors that could limit the fund’s overall appeal.

Positive Factors

Focused Exposure to a Major Pharma Name

The ETF is built almost entirely around AstraZeneca, a large, established healthcare company with a significant presence in global pharmaceuticals.

Defensive Healthcare Sector

Heavy exposure to the healthcare sector can offer some resilience during economic slowdowns, as demand for medicines and treatments tends to be steadier than in more cyclical industries.

Low Expense Ratio

The fund charges a relatively low management fee, which helps investors keep more of any returns generated over time.

Negative Factors

Extreme Single-Stock Concentration

Nearly the entire portfolio is invested in AstraZeneca, meaning the ETF’s performance is highly dependent on the fortunes of one company.

Recent Weak Performance

Both the ETF and its main holding have shown weak year-to-date and recent one-month performance, which may signal short-term pressure on returns.

Lack of Diversification by Sector and Region

With almost all assets in one healthcare stock and effectively all exposure tied to a single market, investors do not get the risk-spreading benefits of a broadly diversified ETF.

AZNH vs. SPDR S&P 500 ETF (SPY)

AUM1.07M

RegionEurope

Expense Ratio0.19%

Beta0.18

IssuerADRhedged

Inception DateOct 01, 2024

Dividend Yield1.08%

Asset ClassEquity

Index TrackedAstraZeneca PLC - Benchmark Price Return

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume6,310

30 Day Avg. Volume4,405

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

59.92

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

AZNH Summary

AZNH is an ETF that mainly tracks the AstraZeneca PLC – Benchmark Price Return index, giving you focused exposure to AstraZeneca, a major global drug and vaccine maker in the health care sector. It invests almost entirely in AstraZeneca stock, which works on treatments in areas like cancer, heart disease, and respiratory illness. Someone might consider this ETF if they believe AstraZeneca’s research and new medicines can drive long-term growth, and they want simple access through a single fund. A key risk is that the ETF is concentrated in one company, so its price can rise or fall sharply with AstraZeneca’s fortunes.

How much will it cost me?The AZNH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific sector and mitigates currency risk while maintaining a streamlined portfolio.

What would affect this ETF?The AZNH ETF could benefit from advancements in pharmaceutical research and development, particularly AstraZeneca's strong pipeline of innovative treatments and its focus on addressing global health challenges. However, potential risks include regulatory changes in the health care sector, competition from other biotech companies, and economic conditions in the U.K. and Europe that may impact the industry. Additionally, while the ADRhedged feature reduces currency risk, broader market volatility could still affect investor sentiment.

AZNH Top 10 Holdings

This ETF is essentially a one-stock story, with AstraZeneca doing almost all the heavy lifting. The fund is tightly tied to the health care world, specifically big pharma and biotech, and it’s almost entirely a U.K.-based bet despite trading via U.S. depositary receipts. AstraZeneca’s recent performance has been mixed—earlier momentum has cooled, and the stock has been losing a bit of steam this year—so when it stumbles, the whole fund feels it. There’s little diversification here: AstraZeneca is the engine, the brakes, and most of the ride.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
AZN	AstraZeneca	98.92%	$1.09M	£210.86B	24.51%	80 Outperform

AZNH Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

54.55

Negative

100DMA

51.83

Positive

200DMA

47.42

Positive

Market Momentum

MACD

-0.12

Positive

RSI

42.65

Neutral

STOCH

29.68

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AZNH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 54.84, equal to the 50-day MA of 54.55, and equal to the 200-day MA of 47.42, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 42.65 is Neutral, neither overbought nor oversold. The STOCH value of 29.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZNH.

AZNH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
AZNH	―	―	$1.07M	0.19%	―
HSBH	―	―	$5.70M	0.19%	―
SHEH	―	―	$2.76M	0.19%	―
BPH	―	―	$1.15M	0.19%	―
ARMH	―	―	$902.83K	0.19%	―
GSKH	―	―	$690.66K	0.19%	―

Performance Comparison

AZNH

AstraZeneca PLC ADRhedged

53.28

9.76

22.43%

HSBH

HSBC Holdings plc ADRhedged

―

SHEH

Shell plc ADRhedged

―

BPH

BP p.l.c. ADRhedged

―

ARMH

Arm Holdings PLC ADRhedged

―

GSKH

GSK plc ADRhedged

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents